Corticoterapia topica a reprezentat un progres important in tratamentul lupusului eritematos, in forma cronica putand sa duca la ameliorari evidente, iar in formele subacute si acute sa fie un adjuvant pretios al tratamentului general.

Studiul nostru se refera la 47 cazuri de lupus eritematos (34 cazuri cronice, 3 subacute si 10 acute) ,care au facut tratament topic cu preparate de corticosteroizi, 29 de sex feminin si 18 de sex masculin, 34 si mediul urban si 13 din mediul rural, cu varsta intre 15 si
65 ani. S-au folosit compusi neflorurati ca: Advantan (14 cazuri), Locoid (14 cazuri), Elocom (11 cazuri), Hidrocortizon acetat (6 cazuri); sau fluorati ca: Pivalat de flumetazon (14 cazuri), Diprosalic (4 cazuri), Cutivate (3 cazuri), Diprogenta (2 cazuri), Triamcinolon acetonid (2 cazuri), Fluocinolon acetonid (1 caz), Dermovate (1 caz).

In lupusul eritematos cronic cutanat, corticosteroizi topici au fost folositi singuri in 10 cazuri sau asociati terapiei generale (hidroxiclorochin, prednison) in 24 cazuri. S-au preferat compusi neflorurati puternici sau cu actiune moderata in aplicatii simple sau sub pansament ocluziv initial, actiunea asupra eritemului si infiltratiei fiind evidenta in 15-20 zile. In lupusul eritematos subacut si acut (sistemic) corticosteroizi topici au fost intotdeauna asociati corticoterapiei generale ducand la ameliorarea mai rapida a leziunilor cutanate.

Topical corticosteroids represented an important progress in the management of lupus erythematosus, being effective in the chronic cases and a valuable adjuvant in the general treatment of subacute and acute cases.

Our study included 47 cases of lupus erythematosus (34 chronic, 3 subacute and 10 acute cases) who received topical corticosteroids. There were 29 females and 18 males aged 13 from rural areas. Nonfluorinated compounds such as Advantan (14 cases), Locoid (14 cases), Elocom (11 cases), Hydrocortisone acetate (6 cases) or fluorinated compounds as Flumethasone pivalate (14 cases), Diprosalic 84 cases), Cutivate (3 cases), Diprogenta (2 cases), Trimcinolone acetonide (2 cases), Fluocinolone acetonide (1 case), Dermovate (1 cases) were used.

In chronic cutaneous lupus erythematosus topical corticosteroids were used alone in 10 cases and associated to general therapy (hydroxychoroquine, prednisone) in 24 cases. Powerful or moderate nonfluorinated compounds were preferred, in simple applications or under initial polythene occlusion, their action upon erythema and infiltration being evident within 15-20 days. In subacute and acute (systemic) lupus erythemaosus topical corticosteroids have been always associated to general corticotherapy, inducing an immediate improvement of cutaneous lesions.